<DOC>
	<DOCNO>NCT01439438</DOCNO>
	<brief_summary>This study prospective , open-label , randomize , crossover , single dose , 02 treatment , 02 sequence 02 period . The volunteer receive , period , reference test formulation , accord randomization list , fast condition , order evaluate reference test formulation bioequivalent .</brief_summary>
	<brief_title>Topiramate Bioequivalence Study Brazil - Fast</brief_title>
	<detailed_description>This study prospective , open-label , randomize , crossover , single dose , 02 treatment , 02 seuqences 02 period . The objective confirm two formulation topiramate 100 mg , coat tablet , bioequivalent , oral , single-dose administration fast condition . The test product topiramate 100 mg produce Dr. Reddy 's Laboratories Ltd. reference product Topamax® market Janssen-Cilag Farmacêutica Ltda . Twenty-eight healthy male volunteer evaluate . The volunteer receive , period , test reference formulation , accord randomization list . In period , blood sample collect follow time : 00:00 ( prior administration medication ) ; 00:20 ; 00:40 ; 01:00 ; 01:30 ; 02:00 ; 02:30 ; 03:00 ; 03:30 ; 04:00 ; 05:00 ; 06:00 ; 08:00 ; 12:00 ; 16:00 ; 20:00 ; 24:00 ; 48:00 ; 72:00 ; 96:00 ; 120:00 ; 144:00 ; 168:00 ; 192:00 . The comparative bioavailability two formulation evaluate base statistical comparison relevant pharmacokinetic parameter , obtain data drug concentration blood .</detailed_description>
	<mesh_term>Epilepsy , Tonic-Clonic</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Male Age 18 50 year Body mass index 19 28,5 kg/m2 Good health condition Capable understand study 's nature aim , include risk adverse effect intention cooperate researcher act compliance requirement assay , confirm informed consent 's signature The volunteer know hypersensitivity study drug ( topiramate ) compound chemically related History presence hepatic gastrointestinal illness , condition interferes drug 's absorption , distribution , excretion metabolism History hepatic , renal , pulmonary , gastrointestinal , epileptic , hematologic psychiatric illness ; hypo hypertension etiologic need pharmacologic treatment ; history myocardial infarction , angina and/or heart insufficiency Nonrecommended electrocardiographic finding , accord investigator criterion , study 's participation The result laboratory exams value consider normal accord protocol 's rule , unless consider clinically irrelevant investigator The volunteer smoker The volunteer ingest 5 cup coffee tea day Has history alcohol drug abuse Use regular drug within 02 week precede begin treatment assessment date , employ drug interfere study within one week The volunteer hospitalize reason within 08 week begin study 's first period treatment assessment date Treatment within 03 previous month study know drug present toxic potential important organ The volunteer participate experimental study ingest experimental drug within 06 month precede begin study assessment date The volunteer donate lose 450 mL blood within 03 month precede study initiation donate 1500 mL within 12 month begin study assessment date Consume inductive drug and/or enzymatic inhibitor ( CYP450 hepatic ) , toxic organism present long halflife 's elimination within 04 week precede study 's initiation Consume alcohol 48 hour antecedent admission study along study period Consume food beverage contain grapefruit ( grapefruit ) within 24 hour precede study period History serious adverse reaction hypersensitivity drug The volunteer condition obstruct participation study accord investigator 's judgement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>